Prothya Biosolutions

What Prothya Biosolutions does

Prothya Biosolutions B.V. is a European plasma-derived biopharmaceutical company that fractionates human blood plasma into therapeutic medicines used in immunology and critical care, and offers contract development and manufacturing (CDMO) services to pharmaceutical partners. The company uses advanced protein isolation methods to convert plasma into medicines that treat immune deficiencies, hemophilia, and related conditions, distributing these branded products to healthcare providers and patients worldwide. Its two revenue streams are direct sales of plasma-derived medicinal products under its own brand, and B2B CDMO services that monetize its fractionation knowledge, validated manufacturing infrastructure, and process IP for external healthcare and pharmaceutical counterparties.

The company was formed in 2021 through the integration of Plasma Industries Belgium (PIBe), with roots in the Belgian Red Cross, and Sanquin Plasma Products (SPP), a former subsidiary of the Sanquin Blood Supply Foundation. Prothya draws on over 60 years of combined operational heritage in plasma collection and fractionation across its Belgian (Neder-over-heembeek) and Dutch operating sites, with a workforce of 1,001–5,000 employees. In January 2022 it consolidated European operations by acquiring Prothya Biosolutions Netherlands and Prothya Biosolutions Hungary Kft.

In October 2025, Accord Plasma B.V., a subsidiary of India's Intas Pharmaceuticals, completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries, integrating Prothya into a larger global plasma therapy network with stated objectives to expand patient access to plasma-derived medicines and increase manufacturing capacity. Under Intas/Accord ownership, Prothya's franchise combines legacy European operational depth with the parent's global commercialization footprint in plasma therapeutics.

Name

Prothya Biosolutions

Legal name

Prothya Biosolutions B.V.

Website

https://Prothya.com

Company type

Private

Founded year

1957

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Prothya Biosolutions B.V. is a European biopharmaceutical company that fractionates human blood plasma into therapeutic medicines for immunology and critical care, and offers CDMO manufacturing services to pharmaceutical partners. Acquired by Accord Plasma (Intas Pharmaceuticals) in October 2025, it operates from Belgium and the Netherlands.

Ownership category

akta.pro rank

Product category

Plasma-derived Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)

akta.pro secondary industries

Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Plasma-derived medicines
• Immunology therapeutics
• Critical care biologics
• Plasma protein fractionation
• CDMO services

Headquarters

HQ city

Neder-over-heembeek

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D

Revenue model

1. Plasma-derived Medicinal Products: Prothya produces plasma-derived medicinal products under its own brand for use in immunology and critical care, generating revenue through product sales to healthcare providers and patients.
2. CDMO Services: The company makes its knowledge and infrastructure available to various partners, providing contract development and manufacturing organization services to pharmaceutical and healthcare companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Prothya Biosolutions uses advanced methods to isolate proteins from human blood plasma and converts them into plasma-derived medicinal products for immunology and critical care applications, sold under its own brand. The company also offers Contract Development and Manufacturing Organization (CDMO) services, making its plasma processing knowledge and infrastructure available to pharmaceutical and healthcare partners worldwide.

Product overview

Prothya Biosolutions operates as a plasma-derived medicinal products company offering a portfolio centered on two main offerings: its own branded plasma-derived medicinal products for immunology and critical care applications, and Contract Development and Manufacturing Organization (CDMO) services that make its knowledge, infrastructure, and manufacturing capabilities available to pharmaceutical partners. The company uses advanced protein isolation methods to transform blood plasma into therapeutic medicines. Formed in 2021 through the integration of Plasma Industries Belgium (PIBe) and Sanquin Plasma Products (SPP), the company leverages over 60 years of combined experience in plasma collection and plasma-derived product manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

• Plasma-Derived Medicinal Products Prothya's branded plasma-derived medicinal products used in immunology and critical care, produced by isolating proteins from blood plasma through advanced fractionation methods. These therapies treat conditions such as immune deficiencies and hemophilia and are supplied to healthcare professionals and patients.
• CDMO Services Contract Development and Manufacturing Organization services where Prothya provides its plasma processing knowledge, infrastructure, and manufacturing capabilities to pharmaceutical and healthcare partners for plasma-derived product development and production.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Regional players

• Sanquin Blood Supply Foundation: Sanquin is the former parent of SPP (now part of Prothya) and continues to operate the Dutch blood/plasma collection network that historically supplied Prothya's feed plasma, making it a closely adjacent rather than fully competing entity.

Broad incumbents

• Intas Pharmaceuticals: Intas is the parent of Accord Plasma (Prothya's new owner) and a broad Indian pharmaceutical conglomerate with generics, biosimilars, and plasma operations—related through ownership and corporate plasma strategy rather than direct product overlap.

Direct peers

• Biotest: Biotest develops and produces plasma proteins and biotherapeutic drugs with a focus on immunology, hematology, and intensive care, directly overlapping Prothya's portfolio and European-centric operations.
• Octapharma: Octapharma develops and manufactures plasma-derived proteins for immunology, hematology, and critical care from a European manufacturing base, competing head-to-head with Prothya in the same therapeutic areas.
• CSL Behring: CSL Behring is the global leader in plasma-derived therapeutics (immunoglobulins, albumin, clotting factors) and directly competes with Prothya across the same immunology and critical care product categories and fractionation technology base.
• Grifols: Grifols is one of the world's largest plasma fractionators, producing a near-identical portfolio of immunoglobulins, albumin, and clotting factors, and operates its own plasma collection network—directly comparable to Prothya's integrated model.
• Kedrion Biopharma: Kedrion is a European-headquartered plasma fractionator producing immunoglobulins, coagulation factors, and albumin with national blood-system partnerships—an almost exact analogue of Prothya's Belgian Red Cross and Sanquin roots.
• LFB Biomédicaments: LFB is a French state-linked plasma fractionator offering immunoglobulins, clotting factors, and albumin largely derived from volunteer donations through the French Blood Establishment—comparable to Prothya in both product mix and not-for-profit-rooted plasma sourcing.
• Takeda (Plasma-Derived Therapies): Takeda's Plasma-Derived Therapies business (inherited from Shire/Baxalta) is a direct competitor in immunoglobulin and albumin franchises, sharing Prothya's immunology and critical care focus and global CDMO-style scale-up capabilities.

Emerging players

• ADMA Biologics: ADMA Biologics is a smaller US-focused plasma-derived therapeutics company specializing in immune globulin products for immunodeficiency—partial overlap with Prothya's immunology franchise, but at a much smaller scale and narrow product mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/plasma-industries-belgium

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prothya Biosolutions